Evidence map›Paper›PMID 27251756›Full record

ArticleBMC neuroscience2016

A non-aggressive, highly efficient, enzymatic method for dissociation of human brain-tumors and brain-tissues to viable single-cells.

Ilan Volovitz, Netanel Shapira, Haim Ezer, Aviv Gafni, Merav Lustgarten, Tal Alter, Idan Ben-Horin, Ori Barzilai, Tal Shahar, Andrew Kanner and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Efficient Generation of Paired Single-Cell Multiomics Profiles by Deep Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Ilan VolovitzCancer Immunotherapy Laboratory, Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel. volovitz@yahoo.com.
Netanel ShapiraCancer Immunotherapy Laboratory, Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Haim EzerDepartment of Neurosurgery, Galilee Medical Center, Lohamei HaGeta'ot 5, Nahariya, Israel.
Aviv GafniCancer Immunotherapy Laboratory, Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Merav LustgartenCancer Immunotherapy Laboratory, Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Tal AlterCancer Immunotherapy Laboratory, Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Idan Ben-HorinCancer Immunotherapy Laboratory, Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Ori BarzilaiDepartment of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Tal ShaharDepartment of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Andrew KannerDepartment of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Itzhak FriedDepartment of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Igor VeshchevDepartment of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Rachel GrossmanDepartment of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Zvi RamDepartment of Neurosurgery, Tel Aviv Sourasky Medical Center, Weizmann 6, Tel Aviv, Israel.
Tel Aviv Sourasky Medical Center · ILWestern Galilee Hospital · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConducting research on the molecular biology, immunology, and physiology of brain tumors (BTs) and primary brain tissues requires the use of viably dissociated single cells. Inadequate methods for tissue dissociation generate considerable loss in the quantity of single cells produced and in the produced cells' viability. Improper dissociation may also demote the quality of data attained in functional and molecular assays due to the presence of large quantities cellular debris containing immune-activatory danger associated molecular patterns, and due to the increased quantities of degraded proteins and RNA.

resultsOver 40 resected BTs and non-tumorous brain tissue samples were dissociated into single cells by mechanical dissociation or by mechanical and enzymatic dissociation. The quality of dissociation was compared for all frequently used dissociation enzymes (collagenase, DNase, hyaluronidase, papain, dispase) and for neutral protease (NP) from Clostridium histolyticum. Single-cell-dissociated cell mixtures were evaluated for cellular viability and for the cell-mixture dissociation quality. Dissociation quality was graded by the quantity of subcellular debris, non-dissociated cell clumps, and DNA released from dead cells. Of all enzymes or enzyme combinations examined, NP (an enzyme previously not evaluated on brain tissues) produced dissociated cell mixtures with the highest mean cellular viability: 93 % in gliomas, 85 % in brain metastases, and 89 % in non-tumorous brain tissue. NP also produced cell mixtures with significantly less cellular debris than other enzymes tested. Dissociation using NP was non-aggressive over time-no changes in cell viability or dissociation quality were found when comparing 2-h dissociation at 37 °C to overnight dissociation at ambient temperature.

conclusionsThe use of NP allows for the most effective dissociation of viable single cells from human BTs or brain tissue. Its non-aggressive dissociative capacity may enable ambient-temperature shipping of tumor pieces in multi-center clinical trials, meanwhile being dissociated. As clinical grade NP is commercially available it can be easily integrated into cell-therapy clinical trials in neuro-oncology. The high quality viable cells produced may enable investigators to conduct more consistent research by avoiding the experimental artifacts associated with the presence dead cells or cellular debris.

Indexed as

Bacterial ProteinsBrainBrain NeoplasmsCell SeparationCell SurvivalEnzymesFreezingGliomaHathewaya histolyticaHumansBacterial ProteinsEnzymesBrainBrain metastasisBrain tumorsCollagenaseDispaseDNaseGlioblastomaGliomaNeutral proteaseTissue dissociation

Identifiers

PMID27251756
PMCPMC4888249
OpenAlexW2413993028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.